Key Takeaway: The article discusses a presentation on the pharmacokinetics of phenylbutyrate, which will be featured at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium. The study examines the drug's behavior in both fed and fasted states, contributing valuable insights to metabolic research. This research is expected to enhance understanding of phenylbutyrate's effectiveness.
Price reaction · baseline $7.19 (2024-09-04 close) · hit pre-market · clean, no other ZVRA news in the window
day 0 close · peak
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Research on phenylbutyrate shows promise in pharmacokinetics.
Presentation at a respected symposium indicates credibility.
Focus on both fed and fasted states enhances understanding.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Modeling the pharmacokinetics of phenylbutyrate in fed and fasted states
Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium - 09/06/2024
Download PDF
Download PDF
Frequently Asked Questions
What is the focus of the pharmacokinetics study?
The study focuses on the pharmacokinetics of phenylbutyrate in fed and fasted states.
Where will the findings be presented?
The findings will be presented at the SSIEM 2024 Annual Symposium.
What is phenylbutyrate used for?
Phenylbutyrate is used in the treatment of metabolic disorders.
When is the SSIEM 2024 Annual Symposium scheduled?